Skip to main
ANIK

Anika Therapeutics (ANIK) Stock Forecast & Price Target

Anika Therapeutics (ANIK) Analyst Ratings

Based on 1 analyst ratings
Buy
Strong Buy 0%
Buy 100%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Anika Therapeutics Inc has demonstrated robust revenue growth, with a 21% increase in international osteoarthritis pain revenue and a remarkable 25% growth in its regenerative solutions segment, driven largely by the successful Integrity patch product. The company is also forecasting a significant expansion in procedures and revenue related to Integrity in 2025, bolstered by further opportunities to enhance utilization among current customers and broaden its market reach. Additionally, positive trends in free cash flow and potential improvements in gross margins indicate strengthening operational efficiency, particularly as production issues resolve, which supports a favorable long-term financial outlook.

Bears say

Anika Therapeutics Inc reported a 5.9% decline in revenue, generating $27.8 million, which underscores persistent challenges in maintaining top-line growth amidst ongoing production yield issues. The company's gross margin of 56% fell short of expectations, and the failure of the pivotal FastTrack trial for Hyalofast raises concerns about the effectiveness of its clinical programs, essential for long-term revenue generation. Additionally, significant anticipated declines in Anika's OEM channel revenue, coupled with mixed performance in adjusted EBITDA, contribute to a negative outlook on the company's financial health.

Anika Therapeutics (ANIK) has been analyzed by 1 analysts, with a consensus rating of Buy. 0% of analysts recommend a Strong Buy, 100% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Anika Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Anika Therapeutics (ANIK) Forecast

Analysts have given Anika Therapeutics (ANIK) a Buy based on their latest research and market trends.

According to 1 analysts, Anika Therapeutics (ANIK) has a Buy consensus rating as of Feb 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $16, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $16, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Anika Therapeutics (ANIK)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.